Articles

Antagonism of Immune Effector Function by Ibrutinib or Obinutuzumab versus Rituximab

ASH 2014 – Castleman's Disease

Ibrutinib Alone or in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma

ASH 2014 – Castleman's Disease

Data from the SPARK Study: Mutational Analysis of Patients with Primary Resistance to Ibrutinib in Relapsed/Refractory Mantle-Cell Lymphoma

ASH 2014 – Castleman's Disease

International Research Agenda for Multicentric Castleman’s Disease

ASH 2014 – Castleman's Disease

Updates on Treatments for Castleman’s Disease

ASH 2014 – Castleman's Disease

Pathology and Diagnosis of Multicentric Castleman’s Disease

ASH 2014 – Castleman's Disease

The Clinical Features of Multicentric Castleman's Disease

ASH 2014 – Castleman's Disease

Multicentric Castleman’s Disease Overview and Update on Its Pathogenesis

ASH 2014 – Castleman's Disease

Interim Analysis of Phase 2 ICLL01: Ofatumumab and High-Dose Methylprednisolone in Patients at Highest Risk for Relapsed/Refractory CLL

ASH 2014 – CLL

Functional Evidence that Ibrutinib Blocks Leukemia Cell Proliferation and Trafficking and Promotes Leukemia Cell Death

ASH 2014 – CLL

Page 136 of 147